<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FRAGMIN- dalteparin sodium injection </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN.<br><br>FRAGMIN<span class="Sup">®</span> (dalteparin sodium) Injection, for subcutaneous use<br>Initial U.S. Approval: 1994</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span> </p>
<ul class="Disc">
<li><span class="Bold">Use of indwelling epidural catheters</span></li>
<li><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.</span></li>
<li><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li><span class="Bold">Optimal timing between the administration of FRAGMIN and neuraxial  procedures is not known</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</span> </p>
<p class="Highlighta"><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S7">Drug Interactions (7)</a></span>].</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="85%">
<col align="right" valign="bottom" width="15%">
<tbody class="Headless">
<tr>
<td align="left"><a href="#BOX">Boxed Warning</a></td>
<td align="right">1/2015</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> including Spinal / <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">Epidural Hematoma</span> (<a href="#S5.1">5.1</a>)</td>
<td align="right">1/2015</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Adult Dosage (<a href="#S2.1">2.1</a>)</td>
<td align="right">6/2015</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span> </p>
<ul class="Disc">
<li><span class="Bold">Use of indwelling epidural catheters</span></li>
<li><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.</span></li>
<li><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li><span class="Bold">Optimal timing between the administration of FRAGMIN and neuraxial  procedures is not known</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</span> </p>
<p class="Highlighta"><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S7">Drug Interactions (7)</a></span>].</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FRAGMIN is a low molecular weight heparin (LMWH) indicated for </p>
<ul class="Disc">
<li> Prophylaxis of ischemic complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#S1.1">1.1</a>)</li>
<li> Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness (<a href="#S1.2">1.2</a>)</li>
<li> Extended treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months (<a href="#S1.3">1.3</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">Limitations of Use</span> </p>
<p class="Highlighta">FRAGMIN is not indicated for the acute treatment of VTE. </p>
</div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="70%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Indication</th>
<th class="Rrule" align="left">Dosing Regimen</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable angina</span> and non-Q-wave MI</td>
<td class="Rrule" align="left">120 IU/kg subcutaneous every 12 hours (with aspirin) (<a href="#S2.1">2.1</a>)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">DVT prophylaxis in abdominal surgery</td>
<td class="Rrule" align="left">2,500 IU subcutaneous once daily or 5,000 IU subcutaneous once daily or 2,500 IU subcutaneous followed by 2,500 IU subcutaneous 12 hours later and then 5,000 IU subcutaneous once daily (<a href="#S2.1">2.1</a>)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">DVT prophylaxis in hip replacement surgery</td>
<td class="Rrule" align="left">
<span class="Bold">Postoperative start –</span> 2,500 IU subcutaneous 4 to 8 hours after surgery, then 5,000 IU subcutaneous once daily or <span class="Bold">Preoperative start – day of surgery</span> 2,500 IU subcutaneous 2 hours before surgery followed by 2,500 IU subcutaneous 4 to 8 hours after surgery, then 5,000 IU subcutaneous once daily (<a href="#S2.1">2.1</a>)<br><span class="Bold">Preoperative start – Evening Before Surgery </span>5,000 IU subcutaneous followed by 5,000 IU subcutaneous 4 to 8 hours after surgery (<a href="#S2.1">2.1</a>)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">DVT prophylaxis in medical patients</td>
<td class="Rrule" align="left">5,000 IU subcutaneous once daily (<a href="#S2.1">2.1</a>)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Extended treatment of VTE in patients with cancer</td>
<td class="Rrule" align="left">Month 1: 200 IU/kg subcutaneous once daily (<a href="#S2.1">2.1</a>)<br>Months 2 – 6: 150 IU/kg subcutaneous once daily (<a href="#S2.1">2.1</a>)</td>
</tr>
</tbody>
</table>
<p class="Highlighta">Do not use as intramuscular injection. FRAGMIN should not be mixed with other injections or infusions (<a href="#S2">2</a>) </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div><div>
<div></div>
<div></div>
</div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li> Single-dose prefilled syringe: 2,500 IU/ 0.2 mL, 5,000 IU/ 0.2 mL. 7,500 IU/ 0.3 mL, 12,500 IU/ 0.5 mL, 15,000 IU/ 0.6 mL, 18,000 IU/ 0.72 mL (<a href="#S3">3</a>)</li>
<li> Single-dose graduated syringe: 10,000 IU/ mL (<a href="#S3">3</a>)</li>
<li> Multiple dose vial: 95,000 IU/3.8 mL (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li> Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S4">4</a>)</li>
<li> History of heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to dalteparin sodium (<a href="#S4">4</a>, <a href="#S6.1">6.1</a>)</li>
<li> In patients undergoing Epidural/Neuraxial anesthesia, do not administer FRAGMIN [<span class="Italics">see <a href="#BOX">Boxed Warning </a></span>(<a href="#S4">4</a>)]; 						<ul class="Circle">
<li> As a treatment for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave MI</li>
<li> For prolonged VTE prophylaxis.(<a href="#S4">4</a>)</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to heparin or pork products (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Use caution in conditions with increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (<a href="#S5.1">5.1</a>)</li>
<li> Monitor <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> of any degree closely (<a href="#S5.2">5.2</a>)</li>
<li> Multiple-dose formulations contain benzyl alcohol (<a href="#S5.3">5.3</a>)</li>
<li> Periodic blood counts recommended (<a href="#S5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reaction is <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> at the injection site (<a href="#S6">6</a>)<br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Use FRAGMIN with care in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents (<a href="#S7">7</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Safety and effectiveness in pediatric patients have not been established (<a href="#S8.4">8.4</a>)</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMAS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Extended Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> in Patients with Cancer</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Adult Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Reductions for <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> in Patients with Cancer and Acute Symptomatic VTE</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Reductions for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> in Extended Treatment of Acute Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> in Patients with Cancer</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> including Spinal / <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">Epidural Hematoma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Benzyl Alcohol Preservative Risk to Premature Infants</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Patients Following Hip Replacement Surgery</a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications</a></h2>
<h2><a href="#section-13.4" class="toc">14.4	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients at Risk for Thromboembolic Complications Due to Severely Restricted Mobility During Acute Illness</a></h2>
<h2><a href="#section-13.5" class="toc">14.5	Patients with Cancer and Acute Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMAS</span></span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span></span></p>
<ul class="Disc">
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Use of indwelling epidural catheters</span></span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.</span></span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known</span></span></li>
</ul>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, when concurrently administered with aspirin therapy [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></h2>
<p class="First">FRAGMIN is also indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), which may lead to <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE):</p>
<ul class="Disc">
<li> In patients undergoing hip replacement surgery [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>];</li>
<li> In patients undergoing abdominal surgery who are at risk for thromboembolic complications [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3)</a></span>];</li>
<li> In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [<span class="Italics">see <a href="#S14.4">Clinical Studies (14.4)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Extended Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> in Patients with Cancer</h2>
<p class="First">FRAGMIN is also indicated for the extended treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [<span class="Italics">see <a href="#S14.5">Clinical Studies (14.5)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.3.1"></a><p></p>
<p class="First"><span class="Bold">Limitations of Use</span></p>
<p>FRAGMIN is not indicated for the acute treatment of VTE.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">FRAGMIN is administered by subcutaneous injection. It must not be administered by intramuscular injection.</p>
<p>FRAGMIN Injection should not be mixed with other injections or infusions unless specific compatibility data are available that support such mixing.</p>
<p>Routine coagulation tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time (PT) and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated Partial Thromboplastin Time</span> (APTT) are relatively insensitive measures of FRAGMIN activity and, therefore, unsuitable for monitoring the anticoagulant effect of FRAGMIN [<span class="Italics">see <a href="#S5">Warnings and Precautions (5)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Adult Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span><span class="Italics">:</span> In patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the recommended dose of FRAGMIN Injection is 120 IU/kg of body weight, but not more than 10,000 IU, subcutaneously every 12 hours with concurrent oral aspirin (75 to 165 mg once daily) therapy. Treatment should be continued until the patient is clinically stabilized. The usual duration of administration is 5 to 8 days. Concurrent aspirin therapy is recommended except when contraindicated.</p>
<p style="border-left:1px solid;"><span class="XmChange">Table 1 lists the volume of FRAGMIN in mL (based on the 3.8 mL multiple-dose vial 25,000 IU/ mL) and quantity of Fragmin in IU, to be administered for a range of patient weights.</span></p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1 Quantity and Volume of FRAGMIN to be Administered by Patient Weight</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="12%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Patient weight (lb)</td>
<td class="Rrule" align="center">&lt; 110</td>
<td class="Rrule" align="center">110 to 131</td>
<td class="Rrule" align="center">132 to 153</td>
<td class="Rrule" align="center">154 to 175</td>
<td class="Rrule" align="center">176 to 197</td>
<td class="Rrule" align="center">≥198</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Patient weight (kg)</td>
<td class="Rrule" align="center">&lt; 50</td>
<td class="Rrule" align="center">50 to 59</td>
<td class="Rrule" align="center">60 to 69</td>
<td class="Rrule" align="center">70 to 79</td>
<td class="Rrule" align="center">80 to 89</td>
<td class="Rrule" align="center">≥90</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Quantity of FRAGMIN (IU)</td>
<td class="Rrule" align="center">5,500 IU</td>
<td class="Rrule" align="center">6,500 IU</td>
<td class="Rrule" align="center">7,500 IU</td>
<td class="Rrule" align="center">9,000 IU</td>
<td class="Rrule" align="center">10,000 IU</td>
<td class="Rrule" align="center">10,000 IU</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Volume of FRAGMIN (mL) 95,000 IU / 3.8 mL</td>
<td class="Rrule" align="center">0.22</td>
<td class="Rrule" align="center">0.26</td>
<td class="Rrule" align="center">0.30</td>
<td class="Rrule" align="center">0.36</td>
<td class="Rrule" align="center">0.40</td>
<td class="Rrule" align="center">0.40</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Prophylaxis of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> Following Hip Replacement Surgery</span><span class="Italics">:</span> Table 2 presents the dosing options for patients undergoing hip replacement surgery. The usual duration of administration is 5 to 10 days after surgery; up to 14 days of treatment with FRAGMIN have been well tolerated in clinical trials.</p>
<a name="table2"></a><table width="50%">
<caption><span>Table 2 Dosing Options for Patients Undergoing Hip Replacement Surgery</span></caption>
<col align="left" valign="middle" width="24%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Timing of First Dose of FRAGMIN</th>
<th class="Rrule" align="center" colspan="4">Dose of FRAGMIN to be Given Subcutaneously</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">10 to 14 Hours Before Surgery</th>
<th class="Rrule" align="center">Within 2 Hours Before Surgery</th>
<th class="Rrule" align="center">4 to 8 Hours After Surgery<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Postoperative Period<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Or later, if hemostasis has not been achieved.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd> Up to 14 days of treatment was well tolerated in controlled clinical trials, where the usual duration of treatment was 5 to 10 days postoperatively.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Allow a minimum of 6 hours between this dose and the dose to be given on Postoperative Day 1. Adjust the timing of the dose on Postoperative Day 1 accordingly.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Allow approximately 24 hours between doses.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Postoperative Start</td>
<td class="Rrule" align="center">---</td>
<td class="Rrule" align="center">---</td>
<td class="Rrule" align="center">2,500 IU<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">5,000 IU once daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Preoperative Start - Day of<br>Surgery</td>
<td class="Rrule" align="center">---</td>
<td class="Rrule" align="center">2,500 IU</td>
<td class="Rrule" align="center">2,500 IU<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">5,000 IU once daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Preoperative Start - Evening Before Surgery<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">5,000 IU</td>
<td class="Rrule" align="center">---</td>
<td class="Rrule" align="center">5,000 IU</td>
<td class="Rrule" align="center">5,000 IU once daily</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Abdominal Surgery</span>: </span>In patients undergoing abdominal surgery with a risk of thromboembolic complications, the recommended dose of FRAGMIN is 2,500 IU administered by subcutaneous injection once daily, starting 1 to 2 hours prior to surgery and repeated once daily postoperatively. The usual duration of administration is 5 to 10 days.</p>
<p>In patients undergoing abdominal surgery associated with a high risk of thromboembolic complications, such as malignant disorder, the recommended dose of FRAGMIN is 5,000 IU subcutaneously the evening before surgery, then once daily postoperatively. The usual duration of administration is 5 to 10 days. Alternatively, in patients with malignancy, 2,500 IU of FRAGMIN can be administered subcutaneously 1 to 2 hours before surgery followed by 2,500 IU subcutaneously 12 hours later, and then 5,000 IU once daily postoperatively. The usual duration of administration is 5 to 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Medical Patients During Acute Illness</span>: </span>In medical patients with severely restricted mobility during acute illness, the recommended dose of FRAGMIN is 5,000 IU administered by subcutaneous injection once daily. In clinical trials, the usual duration of administration was 12 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Extended Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> in Patients with Cancer</span>: </span>In patients with cancer and symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>, the recommended dosing of FRAGMIN is as follows: for the first 30 days of treatment administer FRAGMIN 200 IU/kg total body weight subcutaneously once daily. The total daily dose should not exceed 18,000 IU. Table 3 lists the dose of FRAGMIN to be administered once daily during the first month for a range of patient weights</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5.1"></a><p></p>
<p class="First"><span class="Bold Italics">Month 1</span></p>
<a name="table3"></a><table width="50%">
<caption><span>Table 3 Dose of FRAGMIN to be Administered Subcutaneously by Patient Weight during the First Month</span></caption>
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Body Weight (lbs)</th>
<th class="Rrule" align="center">Body Weight (kg)</th>
<th class="Rrule" align="center">FRAGMIN Dose (IU) (prefilled syringe) once daily</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">≤ 124</td>
<td class="Rrule" align="center">≤ 56</td>
<td class="Rrule" align="center">10,000</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">125 to 150</td>
<td class="Rrule" align="center">57 to 68</td>
<td class="Rrule" align="center">12,500</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">151 to 181</td>
<td class="Rrule" align="center">69 to 82</td>
<td class="Rrule" align="center">15,000</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">182 to 216</td>
<td class="Rrule" align="center">83 to 98</td>
<td class="Rrule" align="center">18,000</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥ 217</td>
<td class="Rrule" align="center">≥ 99</td>
<td class="Rrule" align="center">18,000</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5.2"></a><p></p>
<p class="First"><span class="Bold Italics">Months 2 to 6</span></p>
<p>Administer FRAGMIN at a dose of approximately 150 IU/kg, subcutaneously once daily during Months 2 through 6. The total daily dose should not exceed 18,000 IU. Table 4 lists the dose of FRAGMIN to be administered once daily for a range of patient weights during months 2–6.</p>
<a name="table4"></a><table width="50%">
<caption><span>Table 4 Dose of FRAGMIN to be Administered Subcutaneously by Patient Weight during Months 2–6</span></caption>
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Body Weight (lbs)</th>
<th class="Rrule" align="center">Body Weight (kg)</th>
<th class="Rrule" align="center">FRAGMIN Dose (IU) (prefilled syringe) once daily</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">≤ 124</td>
<td class="Rrule" align="center">≤ 56</td>
<td class="Rrule" align="center">7,500</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">125 to 150</td>
<td class="Rrule" align="center">57 to 68</td>
<td class="Rrule" align="center">10,000</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">151 to 181</td>
<td class="Rrule" align="center">69 to 82</td>
<td class="Rrule" align="center">12,500</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">182 to 216</td>
<td class="Rrule" align="center">83 to 98</td>
<td class="Rrule" align="center">15,000</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥ 217</td>
<td class="Rrule" align="center">≥ 99</td>
<td class="Rrule" align="center">18,000</td>
</tr>
</tbody>
</table>
<p>Safety and efficacy beyond six months have not been evaluated in patients with cancer and acute symptomatic VTE [<span class="Italics">see <a href="#S5">Warnings and Precaution (5)</a></span> and<span class="Italics"><a href="#S6.1"> Adverse Reactions (6.1)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Reductions for <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> in Patients with Cancer and Acute Symptomatic VTE</h2>
<p class="First">In patients receiving FRAGMIN who experience platelet counts between 50,000 and 100,000/mm<span class="Sup">3</span>, reduce the daily dose of FRAGMIN by 2,500 IU until the platelet count recovers to ≥100,000/mm<span class="Sup">3</span>. In patients receiving FRAGMIN who experience platelet counts &lt; 50,000/mm<span class="Sup">3</span>, discontinue FRAGMIN until the platelet count recovers above 50,000/mm<span class="Sup">3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Reductions for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> in Extended Treatment of Acute Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> in Patients with Cancer</h2>
<p class="First">In patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (CrCl &lt; 30 mL/min), monitor anti-Xa levels to determine the appropriate FRAGMIN dose. Target anti-Xa range is 0.5–1.5 IU/mL. When monitoring anti-Xa in these patients, perform sampling 4–6 hrs after FRAGMIN dosing and only after the patient has received 3–4 doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Administration</h2>
<p class="First">Subcutaneous injection technique: Patients should be sitting or lying down and FRAGMIN administered by deep subcutaneous injection. FRAGMIN may be injected in a U-shape area around the navel, the upper outer side of the thigh or the upper outer quadrangle of the buttock. The injection site should be varied daily. When the area around the navel or the thigh is used, using the thumb and forefinger, you <span class="Bold">must</span> lift up a fold of skin while giving the injection. The entire length of the needle should be inserted at a 45 to 90 degree angle.</p>
<p>Inspect FRAGMIN prefilled syringes and vials visually for particulate matter and discoloration prior to administration</p>
<p>After first penetration of the rubber stopper, store the multiple-dose vials at room temperature for up to 2 weeks. Discard any unused solution after 2 weeks.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Bold">Instructions for using the prefilled single-dose syringes preassembled with needle guard devices</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-01.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Fixed dose syringes:</span> To ensure delivery of the full dose, do not expel the air bubble from the prefilled syringe before injection. Hold the syringe assembly by the open sides of the device. Remove the needle shield. Insert the needle into the injection area as instructed above. Depress the plunger of the syringe while holding the finger flange <span class="Bold Underline">until the entire dose has been given</span>. The needle guard will <span class="Bold">not</span> be activated unless the <span class="Bold">entire</span> dose has been given. Remove needle from the patient. Let go of the plunger and allow syringe to move up inside the device until the entire needle is guarded. Discard the syringe assembly in approved containers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Graduated syringes:</span> Hold the syringe assembly by the open sides of the device. Remove the needle shield. With the needle pointing up, prepare the syringe by expelling the air bubble and then continuing to push the plunger to the desired dose or volume, discarding the extra solution in an appropriate manner. Insert the needle into the injection area as instructed above. Depress the plunger of the syringe while holding the finger flange <span class="Bold Underline">until the entire dose remaining in the syringe has been given</span>. The needle guard will <span class="Bold">not</span> be activated unless the <span class="Bold">entire</span> dose has been given. Remove needle from the patient. Let go of the plunger and allow syringe to move up inside the device until the entire needle is guarded. Discard the syringe assembly in approved containers.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">2,500 IU / 0.2 mL single-dose prefilled syringe</p>
<p>5,000 IU / 0.2 mL single-dose prefilled syringe</p>
<p>7,500 IU / 0.3 mL single-dose prefilled syringe</p>
<p>10,000 IU / mL single-dose graduated syringe</p>
<p>12,500 IU / 0.5 mL single-dose prefilled syringe</p>
<p>15,000 IU / 0.6 mL single-dose prefilled syringe</p>
<p>18,000 IU / 0.72 mL single-dose prefilled syringe</p>
<p>95,000 IU / 3.8 mL multiple-dose vial (25,000 IU / mL)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disc">
<li> Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li> History of heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to dalteparin sodium (e.g., pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>) [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>].</li>
<li> In patients undergoing Epidural/Neuraxial anesthesia, do not administer FRAGMIN [<span class="Italics">see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]; 						<ul class="Circle">
<li>As a treatment for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave MI.</li>
<li>For prolonged VTE prophylaxis.</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to heparin or pork products.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> including Spinal / <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">Epidural Hematoma</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Spinal or epidural <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and subsequent <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> can occur with the associated use of low molecular weight heparins or heparinoids and neuraxial (spinal/epidural) anesthesia or spinal puncture. The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> [<span class="Italics">see <a href="#BOX">Boxed Warning</a></span> and<span class="Italics"><a href="#S6.2"> Adverse Reactions (6.2)</a> and <a href="#S7">Drug Interactions (7)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">To reduce the potential risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concurrent use of dalteparin sodium and epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or spinal puncture, consider the pharmacokinetic profile of dalteparin [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dalteparin is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. No additional hemostasis-altering medications should be administered due to the additive effects.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients on preoperative FRAGMIN thromboprophylaxis can be assumed to have altered coagulation. The first postoperative FRAGMIN thrombophylaxis dose (2,500 IU) should be administered 6 to 8 hrs postoperatively. The second postoperative dose (2,500 or 5,000 IU) should occur no sooner than 24 hrs after the first dose. Placement or removal of a catheter should be delayed for at least 12 hours after administration of 2,500 IU once daily of FRAGMIN, at least 15 hours after the administration of 5,000 IU once daily of FRAGMIN, and at least 24 hours after the administration of higher doses (200 IU/kg once daily, 120 IU/kg twice daily) of FRAGMIN. Anti-Xa levels are still detectable at these time points, and these delays are not a guarantee that neuraxial <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> will be avoided.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Although a specific recommendation for timing of a subsequent FRAGMIN dose after catheter removal cannot be made, consider delaying this next dose for at least four hours, based on a benefit-risk assessment considering both the risk for <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and the risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the context of the procedure and patient risk factors. For patients with creatinine clearance &lt;30mL/minute, additional considerations are necessary because elimination of FRAGMIN may be more prolonged; consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of FRAGMIN (2,500 IU or 5,000 IU once daily) and at least 48 hours for the higher dose (200 IU/kg once daily, 120 IU/kg twice daily) [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, sensory and motor deficits (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in lower limbs), bowel and/or bladder dysfunction. Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Use FRAGMIN with extreme caution in patients who have an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, such as those with severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, <span class="product-label-link" type="condition" conceptid="4116649" conceptname="Bacterial endocarditis">bacterial endocarditis</span>, congenital or acquired <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders, active ulceration and angiodysplastic gastrointestinal disease, <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>, or shortly after brain, spinal or ophthalmological surgery. FRAGMIN may enhance the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or platelet defects; severe liver or kidney insufficiency, hypertensive or <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, and recent <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can occur at any site during therapy with FRAGMIN.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced thrombocytopenia</span> can occur with the administration of FRAGMIN. The incidence of this complication is unknown at present. In clinical practice, cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, amputation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been observed [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>]. Closely monitor <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> of any degree.</p>
<p>In FRAGMIN clinical trials supporting non-cancer indications, platelet counts of &lt; 50,000/mm<span class="Sup">3</span> occurred in &lt; 1% of patients.</p>
<p>In the clinical trial of patients with cancer and acute symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> treated for up to 6 months in the FRAGMIN treatment arm, platelet counts of &lt; 100,000/mm<span class="Sup">3</span> occurred in 13.6% of patients, including 6.5% who also had platelet counts less than 50,000/mm<span class="Sup">3</span>. In the same clinical trial, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was reported as an adverse event in 10.9% of patients in the FRAGMIN arm and 8.1% of patients in the OAC arm. FRAGMIN dose was decreased or interrupted in patients whose platelet counts fell below 100,000/mm<span class="Sup">3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Benzyl Alcohol Preservative Risk to Premature Infants</h2>
<p class="First">Each multiple-dose vial of FRAGMIN contains benzyl alcohol as a preservative. Benzyl alcohol has been reported to be associated with a fatal "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Gasping</span> Syndrome" in premature infants. Because benzyl alcohol may cross the placenta, use caution when administering FRAGMIN preserved with benzyl alcohol to pregnant women. If anticoagulation with FRAGMIN is needed during pregnancy, use preservative-free formulations, where possible [<span class="Italics">see <a href="#S8.1">Use in Specific Populations (8.1)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Laboratory Tests</h2>
<p class="First">Periodic routine complete blood counts, including platelet count, blood chemistry, and stool occult blood tests are recommended during the course of treatment with FRAGMIN. When administered at recommended prophylaxis doses, routine coagulation tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time (PT) and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated Partial Thromboplastin Time</span> (APTT) are relatively insensitive measures of FRAGMIN activity and, therefore, unsuitable for monitoring the anticoagulant effect of FRAGMIN. Anti-Factor Xa may be used to monitor the anticoagulant effect of FRAGMIN, such as in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or if abnormal coagulation parameters or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs during FRAGMIN therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">The following serious adverse reactions are described in more detail in other sections of the prescribing information.</span></p>
<ul class="Disc">
<li> Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> including Spinal/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">Epidural Hematoma</span> [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</li>
<li> Benzyl Alcohol preservative Risk to Premature Infants [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not accurately reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></p>
<p>The incidence of hemorrhagic complications during treatment with FRAGMIN Injection has been low. The most commonly reported side effect is <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> at the injection site. The risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> varies with the indication and may increase with higher doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></p>
<p>Table 5 summarizes major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions that occurred with FRAGMIN, heparin, and placebo in clinical trials of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Indication</th>
<th class="Rrule" align="center" colspan="3">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave MI</th>
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>120 IU/kg/12 hr subcutaneous<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a><br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Heparin<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></span><br>intravenous and subcutaneous<a href="#footnote-6" class="Sup">†</a><br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Placebo</span><br>every 12 hr subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Treatment was administered for 5 to 8 days.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Heparin intravenous infusion for at least 48 hours, APTT 1.5 to 2 times control, then 12,500 U subcutaneously every 12 hours for 5 to 8 days.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Aspirin (75 to 165 mg per day) and beta blocker therapies were administered concurrently.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> reactions were considered major if: 1) accompanied by a decrease in hemoglobin of ≥2 g/dL in connection with clinical symptoms; 2) a transfusion was required; 3) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> led to interruption of treatment or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>; or 4) intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a>
</td>
<td class="Rrule" align="center">15/1497 (1.0)</td>
<td class="Rrule" align="center">7/731 (1.0)</td>
<td class="Rrule" align="center">4/760 (0.5)</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Hip Replacement Surgery</span></p>
<p>Table 6 summarizes: 1) all major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions and, 2) other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions possibly or probably related to treatment with FRAGMIN (preoperative dosing regimen), warfarin sodium, or heparin in two hip replacement surgery clinical trials.</p>
<a name="table6"></a><table width="100%">
<caption><span>Table 6 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions Following Hip Replacement Surgery</span></caption>
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">FRAGMIN vs Warfarin Sodium</th>
<th class="Rrule" align="center" colspan="2">FRAGMIN vs Heparin</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Hip Replacement Surgery</th>
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span><br>5,000 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Warfarin</span><br>Sodium<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a> oral<br><br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a></span><br>5,000 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Heparin</span><br>5,000 U three times a day subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Includes three treated patients who did not undergo a surgical procedure.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Warfarin sodium dosage was adjusted to maintain a <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time index of 1.4 to 1.5, corresponding to an International Normalized Ratio (INR) of approximately 2.5.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>Includes two treated patients who did not undergo a surgical procedure.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>A <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event was considered major if: 1) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, 2) it was associated with a hemoglobin decrease of ≥2 g/dL or transfusion of 2 or more units of blood products, 3) it resulted in reoperation due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or 4) it involved retroperitoneal or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">¶</a></dt>
<dd>Occurred at a rate of at least 2% in the group treated with FRAGMIN 5,000 IU once daily.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions<a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a>
</td>
<td class="Rrule" align="center">7/274 (2.6)</td>
<td class="Rrule" align="center">1/279 (0.4)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3/69 (4.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions<a name="footnote-reference-13" href="#footnote-13" class="Sup">¶</a><br><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Rrule" align="center">8/274 (2.9)</td>
<td class="Rrule" align="center">5/279 (1.8)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">6/274 (2.2)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Injection Site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">3/274 (1.1)</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">2/69 (2.9)</td>
<td class="Rrule" align="center">7/69 (10.1)</td>
</tr>
</tbody>
</table>
<p>Six of the patients treated with FRAGMIN experienced seven major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions. Two of the reactions were <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> (one requiring reoperation), three were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the operative site, one was <span class="product-label-link" type="condition" conceptid="4308716" conceptname="Intraoperative hemorrhage">intraoperative bleeding</span> due to vessel damage, and one was <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. None of the patients experienced retroperitoneal or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> or died of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications.</p>
<p>In the third hip replacement surgery clinical trial, the incidence of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions was similar in all three treatment groups: 3.6% (18/496) for patients who started FRAGMIN before surgery; 2.5% (12/487) for patients who started FRAGMIN after surgery; and 3.1% (15/489) for patients treated with warfarin sodium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Abdominal Surgery</span></p>
<p>Table 7 summarizes <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions that occurred in clinical trials which studied FRAGMIN 2,500 and 5,000 IU administered once daily to abdominal surgery patients.</p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions Following Abdominal Surgery</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="26%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">FRAGMIN vs Placebo</th>
<th class="Rrule" align="center" colspan="2">FRAGMIN vs FRAGMIN</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Abdominal Surgery</th>
<th class="Rrule" align="center">FRAGMIN 2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">Placebo once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">FRAGMIN 2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">FRAGMIN 5,000 IU once daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Postoperative Transfusions</td>
<td class="Rrule" align="center">14/182<br>(7.7)</td>
<td class="Rrule" align="center">13/182<br>(7.1)</td>
<td class="Rrule" align="center">89/1,025<br>(8.7)</td>
<td class="Rrule" align="center">125/1,033<br>(12.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">2/79<br>(2.5)</td>
<td class="Rrule" align="center">2/77<br>(2.6)</td>
<td class="Rrule" align="center">1/1,030<br>(0.1)</td>
<td class="Rrule" align="center">4/1,039<br>(0.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Reoperation Due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
<td class="Rrule" align="center">1/79<br>(1.3)</td>
<td class="Rrule" align="center">1/78<br>(1.3)</td>
<td class="Rrule" align="center">2/1,030<br>(0.2)</td>
<td class="Rrule" align="center">13/1,038<br>(1.3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Injection Site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">8/172<br>(4.7)</td>
<td class="Rrule" align="center">2/174<br>(1.1)</td>
<td class="Rrule" align="center">36/1,026<br>(3.5)</td>
<td class="Rrule" align="center">57/1,035<br>(5.5)</td>
</tr>
</tbody>
</table>
<a name="table7cont"></a><table width="100%">
<caption><span>Table 7 Cont. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions Following Abdominal Surgery</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="26%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="4">FRAGMIN vs Heparin</th>
</tr>
<tr class="Botrule"><th class="Rrule" align="center" colspan="4">Dosing Regimen</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Abdominal Surgery</th>
<th class="Rrule" align="center">FRAGMIN 2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">Heparin 5,000 U twice daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">FRAGMIN 5,000 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">Heparin 5,000 U twice daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Postoperative Transfusions</td>
<td class="Rrule" align="center">26/459<br>(5.7)</td>
<td class="Rrule" align="center">36/454<br>(7.9)</td>
<td class="Rrule" align="center">81/508<br>(15.9)</td>
<td class="Rrule" align="center">63/498<br>(12.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">16/467<br>(3.4)</td>
<td class="Rrule" align="center">18/467<br>(3.9)</td>
<td class="Rrule" align="center">12/508<br>(2.4)</td>
<td class="Rrule" align="center">6/498<br>(1.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Reoperation Due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
<td class="Rrule" align="center">2/392<br>(0.5)</td>
<td class="Rrule" align="center">3/392<br>(0.8)</td>
<td class="Rrule" align="center">4/508<br>(0.8)</td>
<td class="Rrule" align="center">2/498<br>(0.4)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Injection Site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td class="Rrule" align="center">1/466<br>(0.2)</td>
<td class="Rrule" align="center">5/464<br>(1.1)</td>
<td class="Rrule" align="center">36/506<br>(7.1)</td>
<td class="Rrule" align="center">47/493<br>(9.5)</td>
</tr>
</tbody>
</table>
<p>In a trial comparing FRAGMIN 5,000 IU once daily to FRAGMIN 2,500 IU once daily in patients undergoing surgery for malignancy, the incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions was 4.6% and 3.6%, respectively (n.s.). In a trial comparing FRAGMIN 5,000 IU once daily to heparin 5,000 U twice daily, in the malignancy subgroup the incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions was 3.2% and 2.7%, respectively for FRAGMIN and Heparin (n.s.).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.4"></a><p></p>
<p class="First"><span class="Bold Italics">Medical Patients with Severely Restricted Mobility During Acute Illness</span></p>
<p>Table 8 summarizes major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions that occurred in a clinical trial of medical patients with severely restricted mobility during acute illness.</p>
<a name="table8"></a><table width="100%">
<caption><span>Table 8 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions in Medical Patients with Severely Restricted Mobility During Acute Illness</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Medical Patients with Severely Restricted Mobility</th>
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>5,000 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Placebo</span><br>once daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>A <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event was considered major if: 1) it was accompanied by a decrease in hemoglobin of ≥2 g/dL in connection with clinical symptoms; 2) intraocular, spinal/epidural, intracranial, or retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; 3) required transfusion of ≥ 2 units of blood products; 4) required significant medical or <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>; or 5) led to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> at Day 14</td>
<td class="Rrule" align="center">8/1,848 (0.4)</td>
<td class="Rrule" align="center">0/1,833 (0)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions<a href="#footnote-14" class="Sup">*</a> at Day 21</td>
<td class="Rrule" align="center">9/1,848 (0.5)</td>
<td class="Rrule" align="center">3/1,833 (0.2)</td>
</tr>
</tbody>
</table>
<p>Three of the major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions that occurred by Day 21 were fatal, all due to <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (two patients in the group treated with FRAGMIN and one in the group receiving placebo).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.5"></a><p></p>
<p class="First"><span class="Bold Italics">Patients with Cancer and Acute Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></span></p>
<p>Table 9 summarizes the number of patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions that occurred in the clinical trial of patients with cancer and acute symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>. A <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event was considered major if it: 1) was accompanied by a decrease in hemoglobin of ≥ 2 g/dL in connection with clinical symptoms; 2) occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>); 3) required transfusion of ≥ 2 units of blood products; or 4) led to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was classified as clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that did not meet criteria for major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>At the end of the six-month study, a total of 46 (13.6%) patients in the FRAGMIN arm and 62 (18.5%) patients in the OAC arm experienced any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event. One <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event (<span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> in a patient in the FRAGMIN arm at Day 71) was fatal.</p>
<a name="table9"></a><table width="75%">
<caption><span>Table 9 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reactions (Major and Any) (As treated population)<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></span></caption>
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Study period</th>
<th class="Rrule" align="center" colspan="3">FRAGMIN 200 IU/kg (max. 18,000 IU) subcutaneous once daily × 1 month, then 150 IU/kg (max. 18,000 IU) subcutaneous once daily × 5 months</th>
<th class="Rrule" align="center" colspan="3">OAC FRAGMIN 200 IU/kg (max 18,000 IU) subcutaneous once daily × 5–7 days and OAC for 6 months (target INR 2–3)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Number at risk</th>
<th class="Rrule" align="center">Patients with Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><br>n (%)</th>
<th class="Rrule" align="center">Patients with Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><br>n (%)</th>
<th class="Rrule" align="center">Number at risk</th>
<th class="Rrule" align="center">Patients with Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><br>n (%)</th>
<th class="Rrule" align="center">Patients with Any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Patients with multiple <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes within any time interval were counted only once in that interval. However, patients with multiple <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that occurred at different time intervals were counted once in each interval in which the event occurred.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Total during study</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">19 (5.6)</td>
<td class="Rrule" align="center">46 (13.6)</td>
<td class="Rrule" align="center">335</td>
<td class="Rrule" align="center">12 (3.6)</td>
<td class="Rrule" align="center">62 (18.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 1</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">4 (1.2)</td>
<td class="Rrule" align="center">15 (4.4)</td>
<td class="Rrule" align="center">335</td>
<td class="Rrule" align="center">4 (1.2)</td>
<td class="Rrule" align="center">12 (3.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Weeks 2–4</td>
<td class="Rrule" align="center">332</td>
<td class="Rrule" align="center">9 (2.7)</td>
<td class="Rrule" align="center">17 (5.1)</td>
<td class="Rrule" align="center">321</td>
<td class="Rrule" align="center">1 (0.3)</td>
<td class="Rrule" align="center">12 (3.7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Weeks 5–28</td>
<td class="Rrule" align="center">297</td>
<td class="Rrule" align="center">9 (3.0)</td>
<td class="Rrule" align="center">26 (8.8)</td>
<td class="Rrule" align="center">267</td>
<td class="Rrule" align="center">8 (3.0)</td>
<td class="Rrule" align="center">40 (15.0)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></p>
<p>[<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Elevations of Serum Transaminases</span></p>
<p>In FRAGMIN clinical trials supporting non-cancer indications, where hepatic transaminases were measured, asymptomatic increases in transaminase levels (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST and SGPT/ALT) greater than three times the upper limit of normal of the laboratory reference range were seen in 4.7% and 4.2%, respectively, of patients during treatment with FRAGMIN.</p>
<p>In the FRAGMIN clinical trial of patients with cancer and acute symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> treated with FRAGMIN for up to 6 months, asymptomatic increases in transaminase levels, AST and ALT, greater than three times the upper limit of normal of the laboratory reference range were reported in 8.9% and 9.5% of patients, respectively. The frequencies of Grades 3 and 4 increases in AST and ALT, as classified by the National Cancer Institute, Common Toxicity Criteria (NCI-CTC) Scoring System, were 3% and 3.8%, respectively. Grades 2, 3 &amp; 4 combined have been reported in 12% and 14% of patients, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Other</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> (i.e., <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>) have occurred. Cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.2"></a><p></p>
<p class="First"><span class="Bold Italics">Local Reactions</span><span class="Italics">:</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at the injection site, the only non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event determined to be possibly or probably related to treatment with FRAGMIN and reported at a rate of at least 2% in the group treated with FRAGMIN, was reported in 4.5% of patients treated with FRAGMIN 5,000 IU once daily vs 11.8% of patients treated with heparin 5,000 U twice daily in the abdominal surgery trials. In the hip replacement trials, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site was reported in 12% of patients treated with FRAGMIN 5,000 IU once daily vs 13% of patients treated with heparin 5,000 U three times a day.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of FRAGMIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Since first international market introduction in 1985, there have been more than 15 reports of epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation with concurrent use of dalteparin sodium and spinal/epidural anesthesia or spinal puncture. The majority of patients had postoperative indwelling epidural catheters placed for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or received additional drugs affecting hemostasis. In some cases the <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> resulted in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> (partial or complete) [<span class="Italics">see <a href="#BOX">Boxed Warning</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">Skin necrosis</span> has occurred. There have been cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> reported that improved on drug discontinuation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Use FRAGMIN with care in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents because of increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [<span class="Italics">see <a href="#S5">Warning and Precautions (5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies of FRAGMIN use in pregnant women. In reproductive and developmental toxicity studies, pregnant rats and rabbits received dalteparin sodium at intravenous doses up to 2,400 IU/kg (14,160 IU/m<span class="Sup">2</span>) (rats) and 4,800 IU/kg (40,800 IU/m<span class="Sup">2</span>) (rabbits). These exposures were 2 to 4 times (rats) and 4 times (rabbits) the human dose of 100 IU/kg dalteparin based on the body surface area. No evidence of impaired fertility or harm to the fetuses occurred in these studies. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Cases of "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Gasping</span> Syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99–404 mg/kg/day). The 9.5 mL and the 3.8 mL multiple-dose vials of FRAGMIN contain 14 mg/mL of benzyl alcohol [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Based on limited published data dalteparin is minimally excreted in human milk. One study of 15 lactating women receiving <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> doses of dalteparin, in the immediate postpartum period, detected small amounts of anti-Xa activity (range &lt; 0.005 to 0.037 IU/ml) in breast milk that were equivalent to a milk/plasma ratio of &lt;0.025–0.224. Oral absorption of LMWH is extremely low, but the clinical implications, if any, of this small amount of anticoagulant activity on a nursing infant are unknown. Caution should be exercised when FRAGMIN is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in clinical studies of FRAGMIN, 5516 patients were 65 years of age or older and 2237 were 75 or older. No overall differences in effectiveness were observed between these subjects and younger subjects. Some studies suggest that the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with age. Postmarketing surveillance and literature reports have not revealed additional differences in the safety of FRAGMIN between elderly and younger patients. Give careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) in geriatric patients, particularly in those with low body weight (&lt; 45 kg) and those predisposed to decreased renal function [<span class="Italics">see <a href="#S5">Warnings and Precautions (5)</a> and <a href="#S12">Clinical Pharmacology (12)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">An excessive dosage of FRAGMIN Injection may lead to hemorrhagic complications. These may generally be stopped by slow intravenous injection of protamine sulfate (1% solution), at a dose of 1 mg protamine for every 100 anti-Xa IU of FRAGMIN given. If the APTT measured 2 to 4 hours after the first infusion remains prolonged, a second infusion of 0.5 mg protamine sulfate per 100 anti-Xa IU of FRAGMIN may be administered. Even with these additional doses of protamine, the APTT may remain more prolonged than would usually be found following administration of unfractionated heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60 to 75%).</p>
<p>Take particular care to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. Because fatal reactions, often resembling <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported with protamine sulfate, give protamine sulfate only when resuscitation techniques and treatment for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> are readily available. For additional information, consult the labeling of Protamine Sulfate Injection, USP, products.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">FRAGMIN Injection (dalteparin sodium injection) is a sterile, low molecular weight heparin. It is available in single-dose, prefilled syringes preassembled with a needle guard device, and multiple-dose vials. With reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard, each syringe contains either 2,500, 5,000, 7,500, 10,000, 12,500, 15,000 or 18,000 anti-Factor Xa international units (IU), equivalent to 16, 32, 48, 64, 80, 96 or 115.2 mg dalteparin sodium, respectively. Each multiple-dose vial contains either 10,000 or 25,000 anti-Factor Xa IU per 1 mL (equivalent to 64 or 160 mg dalteparin sodium, respectively), for a total of 95,000 anti-Factor Xa IU per vial.</p>
<p>Each prefilled syringe also contains Water for Injection and sodium chloride, when required, to maintain physiologic ionic strength. The prefilled syringes are preservative-free. Each multiple-dose vial also contains Water for Injection and 14 mg of benzyl alcohol per mL as a preservative. The pH of both formulations is 5.0 to 7.5 [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a> and <a href="#S16">How Supplied (16)</a></span>].</p>
<p>Dalteparin sodium is produced through controlled nitrous acid depolymerization of sodium heparin from porcine intestinal mucosa followed by a chromatographic purification process. It is composed of strongly acidic sulfated polysaccharide chains (oligosaccharide, containing 2,5-anhydro-D-mannitol residues as end groups) with an average molecular weight of 5,000 and about 90% of the material within the range 2,000–9,000. The molecular weight distribution is:</p>
<table class="Noautorules" width="50%">
<col align="right" valign="top" width="10%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr>
<td align="right">&lt;</td>
<td align="left">3000 daltons</td>
<td align="left">3.0–15%</td>
</tr>
<tr>
<td align="right"></td>
<td align="left">3,000 to 8,000 daltons</td>
<td align="left">65.0–78.0%</td>
</tr>
<tr>
<td align="right">&gt;</td>
<td align="left">8,000 daltons</td>
<td align="left">14.0–26.0%</td>
</tr>
</tbody>
</table>
<p><span class="Bold">STRUCTURAL FORMULA</span></p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dalteparin is a low molecular weight heparin with antithrombotic properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (APTT).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Doses of FRAGMIN Injection of up to 10,000 anti-Factor Xa IU administered subcutaneously as a single dose or two 5,000 IU doses 12 hours apart to healthy subjects did not produce a significant change in platelet aggregation, <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, or global clotting tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span> (TT) or APTT. Subcutaneous administration of doses of 5,000 IU twice daily of FRAGMIN for seven consecutive days to patients undergoing abdominal surgery did not markedly affect APTT, Platelet Factor 4 (PF4), or lipoprotein lipase.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Mean peak levels of plasma anti-Factor Xa activity following single subcutaneous doses of 2,500, 5,000 and 10,000 IU were 0.19 ± 0.04, 0.41 ± 0.07 and 0.82 ± 0.10 IU/mL, respectively, and were attained in about 4 hours in most subjects. Absolute bioavailability in healthy volunteers, measured as the anti-Factor Xa activity, was 87 ± 6%. Increasing the dose from 2,500 to 10,000 IU resulted in an overall increase in anti-Factor Xa AUC that was greater than proportional by about one-third.</p>
<p>Peak anti-Factor Xa activity increased more or less linearly with dose over the same dose range. There appeared to be no appreciable accumulation of anti-Factor Xa activity with twice-daily dosing of 100 IU/kg subcutaneously for up to 7 days.</p>
<p>The volume of distribution for dalteparin anti-Factor Xa activity was 40 to 60 mL/kg. The mean plasma clearances of dalteparin anti-Factor Xa activity in normal volunteers following single intravenous bolus doses of 30 and 120 anti-Factor Xa IU/kg were 24.6 ± 5.4 and 15.6 ± 2.4 mL/hr/kg, respectively. The corresponding mean disposition half-lives were 1.47 ± 0.3 and 2.5 ± 0.3 hours.</p>
<p>Following intravenous doses of 40 and 60 IU/kg, mean terminal half-lives were 2.1 ± 0.3 and 2.3 ± 0.4 hours, respectively. Longer apparent terminal half-lives (3 to 5 hours) are observed following subcutaneous dosing, possibly due to delayed absorption. In patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> requiring hemodialysis, the mean terminal half-life of anti-Factor Xa activity following a single intravenous dose of 5,000 IU FRAGMIN was 5.7 ± 2.0 hours, i.e. considerably longer than values observed in healthy volunteers, therefore, greater accumulation can be expected in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Dalteparin sodium has not been tested for its carcinogenic potential in long-term animal studies. It was not mutagenic in the <span class="Bold Italics">in vitro</span> Ames Test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation test and human lymphocyte chromosomal aberration test and in the <span class="Bold Italics">in vivo</span> mouse micronucleus test. Dalteparin sodium at subcutaneous doses up to 1,200 IU/kg (7,080 IU/m<span class="Sup">2</span>) did not affect the fertility or reproductive performance of male and female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a double-blind, randomized, placebo-controlled clinical trial, patients who recently experienced <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> with EKG changes or non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) were randomized to FRAGMIN Injection 120 IU/kg or placebo every 12 hours subcutaneously. In this trial, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> was defined to include only angina with EKG changes. All patients, except when contraindicated, were treated concurrently with aspirin (75 mg once daily) and beta blockers. Treatment was initiated within 72 hours of the event (the majority of patients received treatment within 24 hours) and continued for 5 to 8 days. A total of 1506 patients were enrolled and treated; 746 received FRAGMIN and 760 received placebo. The mean age of the study population was 68 years (range 40 to 90 years) and the majority of patients were white (99.7%) and male (63.9%). The combined incidence of the endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was lower for FRAGMIN compared with placebo at 6 days after initiation of therapy. These results were observed in an analysis of all-randomized and all-treated patients. The combined incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, need for intravenous heparin or intravenous. nitroglycerin, and revascularization was also lower for FRAGMIN than for placebo (see <a href="#table10">Table 10</a>).</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10 Efficacy of FRAGMIN in the Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="center" valign="middle" width="40%">
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>120 IU/kg/every 12 hr subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Placebo</span><br>every 12 hr subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>p-value = 0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">All Treated <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave MI Patients</td>
<td class="Rrule" align="center">746</td>
<td class="Rrule" align="center">760</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Primary Endpoints - 6 day timepoint<br><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI</td>
<td class="Rrule" align="center">13/741 (1.8)<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</td>
<td class="Rrule" align="center">36/757 (4.8)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Secondary Endpoints - 6 day timepoint<br><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, intravenous heparin, i.v. nitroglycerin, Revascularization</td>
<td class="Rrule" align="center">59/739 (8.0)<a href="#footnote-16" class="Sup">*</a>
</td>
<td class="Rrule" align="center">106/756 (14.0)</td>
</tr>
</tbody>
</table>
<p>In a second randomized, controlled trial designed to evaluate long-term treatment with FRAGMIN (days 6 to 45), data were also collected comparing 1-week (5 to 8 days) treatment of FRAGMIN 120 IU/kg every 12 hours subcutaneously with heparin at an APTT-adjusted dosage. All patients, except when contraindicated, were treated concurrently with aspirin (100 to 165 mg per day). Of the 1,499 patients enrolled, 1,482 patients were treated; 751 received FRAGMIN and 731 received heparin. The mean age of the study population was 64 years (range 25 to 92 years) and the majority of patients were white (96.0%) and male (64.2%). The incidence of the combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or recurrent angina during this 1-week treatment period (5 to 8 days) was 9.3% for FRAGMIN and 7.6% for heparin (p=0.323).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Patients Following Hip Replacement Surgery</h2>
<p class="First">In an open-label randomized study, FRAGMIN 5,000 IU administered once daily subcutaneously was compared with warfarin sodium, administered orally, in patients undergoing hip replacement surgery. Treatment with FRAGMIN was initiated with a 2,500 IU dose subcutaneously within 2 hours before surgery, followed by a 2,500 IU dose subcutaneously the evening of the day of surgery. Then, a dosing regimen of FRAGMIN 5,000 IU subcutaneously once daily was initiated on the first postoperative day. The first dose of warfarin sodium was given the evening before surgery, then continued daily at a dose adjusted for INR 2 to 3. Treatment in both groups was then continued for 5 to 9 days postoperatively. Of the 580 patients enrolled, 553 were treated and 550 underwent surgery. Of those who underwent surgery, 271 received FRAGMIN and 279 received warfarin sodium. The mean age of the study population was 63 years (range 20 to 92 years) and the majority of patients were white (91.1%) and female (52.9%). The incidence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), as determined by evaluable venography, was significantly lower for the group treated with FRAGMIN compared with patients treated with warfarin sodium (see <a href="#table11">Table 11</a>).</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 11 Efficacy of FRAGMIN in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip Replacement Surgery</span></caption>
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>5,000 IU once daily<a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a> subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Warfarin Sodium</span><br>once daily<a name="footnote-reference-18" href="#footnote-18" class="Sup">†</a> oral<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>The daily dose on the day of surgery was divided: 2,500 IU was given two hours before surgery and again in the evening of the day of surgery.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">†</a></dt>
<dd>Warfarin sodium dosage was adjusted to maintain a <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time index of 1.4 to 1.5, corresponding to an International Normalized Ratio (INR) of approximately 2.5</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">‡</a></dt>
<dd>p-value = 0.006</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">§</a></dt>
<dd>p-value = 0.185</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">All Treated Hip Replacement Surgery Patients</td>
<td class="Rrule" align="center">271</td>
<td class="Rrule" align="center">279</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Treatment Failures in Evaluable Patients DVT, Total</td>
<td class="Rrule" align="center">28/192 (14.6)<a name="footnote-reference-19" href="#footnote-19" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">49/190 (25.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Proximal DVT</td>
<td class="Rrule" align="center">10/192 (5.2)<a name="footnote-reference-20" href="#footnote-20" class="Sup">§</a>
</td>
<td class="Rrule" align="center">16/190 (8.4)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">PE</td>
<td class="Rrule" align="center">2/271 (0.7)</td>
<td class="Rrule" align="center">2/279 (0.7)</td>
</tr>
</tbody>
</table>
<p>In a second single-center, double-blind study of patients undergoing hip replacement surgery, FRAGMIN 5,000 IU once daily subcutaneously starting the evening before surgery, was compared with heparin 5,000 U subcutaneously three times a day, starting the morning of surgery. Treatment in both groups was continued for up to 9 days postoperatively. Of the 140 patients enrolled, 139 were treated and 136 underwent surgery. Of those who underwent surgery, 67 received FRAGMIN and 69 received heparin. The mean age of the study population was 69 years (range 42 to 87 years) and the majority of patients were female (58.8%). In the intent-to-treat analysis, the incidence of proximal DVT was significantly lower for patients treated with FRAGMIN compared with patients treated with heparin (6/67 vs 18/69; p=0.012). The incidence of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> detected by lung scan was also significantly lower in the group treated with FRAGMIN (9/67 vs 19/69; p=0.032).</p>
<p>A third multi-center, double-blind, randomized study evaluated a postoperative dosing regimen of FRAGMIN for thromboprophylaxis following total hip replacement surgery. Patients received either FRAGMIN or warfarin sodium, randomized into one of three treatment groups. One group of patients received the first dose of FRAGMIN 2,500 IU subcutaneous within 2 hours before surgery, followed by another dose of FRAGMIN 2,500 IU subcutaneous at least 4 hours (6.6 ± 2.3 hr) after surgery. Another group received the first dose of FRAGMIN 2,500 IU subcutaneous at least 4 hours (6.6 ± 2.4 hr) after surgery. Then, <span class="Bold">both</span> of these groups began a dosing regimen of FRAGMIN 5,000 IU once daily subcutaneous on postoperative day 1. The third group of patients received warfarin sodium the evening of the day of surgery, then continued daily at a dose adjusted to maintain INR 2 to 3. Treatment for all groups was continued for 4 to 8 days postoperatively, after which time all patients underwent bilateral venography.</p>
<p>In the total enrolled study population of 1,501 patients, 1472 patients were treated; 496 received FRAGMIN (first dose before surgery), 487 received FRAGMIN (first dose after surgery) and 489 received warfarin sodium. The mean age of the study population was 63 years (range 18 to 91 years) and the majority of patients were white (94.4%) and female (51.8%).</p>
<p>Administration of the first dose of FRAGMIN after surgery was as effective in reducing the incidence of thromboembolic reactions as administration of the first dose of FRAGMIN before surgery (44/336 vs 37/338; p=0.448). Both dosing regimens of FRAGMIN were more effective than warfarin sodium in reducing the incidence of thromboembolic reactions following hip replacement surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications</h2>
<p class="First">Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes, or who have additional risk factors such as malignancy or a history of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>FRAGMIN administered once daily subcutaneously beginning prior to surgery and continued for 5 to 10 days after surgery, reduced the risk of DVT in patients at risk for thromboembolic complications in two double-blind, randomized, controlled clinical trials performed in patients undergoing major abdominal surgery. In the first study, a total of 204 patients were enrolled and treated; 102 received FRAGMIN and 102 received placebo. The mean age of the study population was 64 years (range 40 to 98 years) and the majority of patients were female (54.9%). In the second study, a total of 391 patients were enrolled and treated; 195 received FRAGMIN and 196 received heparin. The mean age of the study population was 59 years (range 30 to 88 years) and the majority of patients were female (51.9%). FRAGMIN 2,500 IU was superior to placebo and similar to heparin in reducing the risk of DVT (see <a href="#table12">Tables 12</a> and <a href="#table13">13</a>).</p>
<a name="table12"></a><table width="100%">
<caption><span>Table 12 Efficacy of FRAGMIN in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery</span></caption>
<col align="left" valign="middle" width="45%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Placebo</span><br>once daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-21" href="#footnote-reference-21">*</a></dt>
<dd>p-value = 0.008</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">†</a></dt>
<dd>Both patients also had DVT, 1 proximal and 1 distal</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">All Treated Abdominal Surgery Patients</td>
<td class="Rrule" align="center">102</td>
<td class="Rrule" align="center">102</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Treatment Failures in Evaluable Patients<br>Total Thromboembolic Reactions</td>
<td class="Rrule" align="center">4/91 (4.4)<a name="footnote-reference-21" href="#footnote-21" class="Sup">*</a>
</td>
<td class="Rrule" align="center">16/91 (17.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Proximal DVT</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5/91 (5.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Distal DVT</td>
<td class="Rrule" align="center">4/91 (4.4)</td>
<td class="Rrule" align="center">11/91 (12.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">PE</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2/91 (2.2)<a name="footnote-reference-22" href="#footnote-22" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<a name="table13"></a><table width="100%">
<caption><span>Table 13 Efficacy of FRAGMIN in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery</span></caption>
<col align="left" valign="middle" width="55%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Heparin</span><br>5,000 U twice daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>p-value = 0.74</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">All Treated Abdominal Surgery Patients</td>
<td class="Rrule" align="center">195</td>
<td class="Rrule" align="center">196</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Treatment Failures in Evaluable Patients<br>  Total Thromboembolic Reactions</td>
<td class="Rrule" align="center">7/178 (3.9)<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a>
</td>
<td class="Rrule" align="center">7/174 (4.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Proximal DVT</td>
<td class="Rrule" align="center">3/178 (1.7)</td>
<td class="Rrule" align="center">4/174 (2.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Distal DVT</td>
<td class="Rrule" align="center">3/178 (1.7)</td>
<td class="Rrule" align="center">3/174 (1.7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  PE</td>
<td class="Rrule" align="center">1/178 (0.6)</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>In a third double-blind, randomized study performed in patients undergoing major abdominal surgery with malignancy, FRAGMIN 5,000 IU subcutaneous once daily was compared with FRAGMIN 2,500 IU subcutaneous once daily. Treatment was continued for 6 to 8 days. A total of 1,375 patients were enrolled and treated; 679 received FRAGMIN 5,000 IU and 696 received 2,500 IU. The mean age of the combined groups was 71 years (range 40 to 95 years). The majority of patients were female (51.0%). FRAGMIN 5,000 IU once daily was more effective than FRAGMIN 2,500 IU once daily in reducing the risk of DVT in patients undergoing abdominal surgery with malignancy (see <a href="#table14">Table 14</a>).</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 14 Efficacy of FRAGMIN in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery</span></caption>
<col align="left" valign="middle" width="55%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="23%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>2,500 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>5,000 IU once daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>Major abdominal surgery with malignancy</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd>p-value = 0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">All Treated Abdominal Surgery Patients<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a>
</td>
<td class="Rrule" align="center">696</td>
<td class="Rrule" align="center">679</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Treatment Failures in Evaluable Patients<br>  Total Thromboembolic Reactions</td>
<td class="Rrule" align="center">99/656 (15.1)<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a>
</td>
<td class="Rrule" align="center">60/645 (9.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Proximal DVT</td>
<td class="Rrule" align="center">18/657 (2.7)</td>
<td class="Rrule" align="center">14/646 (2.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Distal DVT</td>
<td class="Rrule" align="center">80/657 (12.2)</td>
<td class="Rrule" align="center">41/646 (6.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  PE</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Fatal</td>
<td class="Rrule" align="center">1/674 (0.1)</td>
<td class="Rrule" align="center">1/669 (0.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">    Non-fatal</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4	Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients at Risk for Thromboembolic Complications Due to Severely Restricted Mobility During Acute Illness</h2>
<p class="First">In a double-blind, multi-center, randomized, placebo-controlled clinical trial, general medical patients with severely restricted mobility who were at risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> were randomized to receive either FRAGMIN 5,000 IU or placebo subcutaneously once daily during Days 1 to 14 of the study. These patients had an acute medical condition requiring a projected hospital stay of at least 4 days, and were confined to bed during waking hours. The study included patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (NYHA Class III or IV), <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> not requiring ventilatory support, and the following acute conditions with at least one risk factor occurring in &gt; 1% of treated patients: acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (excluding <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>), acute rheumatic disorder, acute lumbar or sciatic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, vertebral compression, or <span class="product-label-link" type="condition" conceptid="4000634" conceptname="Acute arthritis">acute arthritis</span> of the lower extremities. Risk factors include &gt; 75 years of age, cancer, previous DVT/PE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> and chronic <span class="product-label-link" type="condition" conceptid="4215941" conceptname="Hypostasis">venous insufficiency</span>. A total of 3,681 patients were enrolled and treated: 1,848 received FRAGMIN and 1,833 received placebo. The mean age of the study population was 69 years (range 26 to 99 years), 92.1% were white and 51.9% were female. The primary efficacy endpoint was evaluated at Day 21 and was defined as at least one of the following within Days 1 to 21 of the study: asymptomatic DVT (diagnosed by compression ultrasound), a confirmed symptomatic DVT, a confirmed <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. The follow-up extended through Day 90.</p>
<p>When given at a dose of 5,000 IU once a day subcutaneously, FRAGMIN significantly reduced the incidence of thromboembolic reactions including verified DVT by Day 21 (see <a href="#table15">Table 15</a>). The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> effect was sustained through Day 90.</p>
<a name="table15"></a><table width="100%">
<caption><span>Table 15 Efficacy of FRAGMIN in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients with Severely Restricted Mobility During Acute Illness</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Indication</th>
<th class="Rrule" align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">FRAGMIN</span><br>5,000 IU once daily subcutaneous<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Placebo</span><br>once daily subcutaneous<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-26" href="#footnote-reference-26">*</a></dt>
<dd>Defined as DVT (diagnosed by compression ultrasound at Day 21 + 3),   confirmed symptomatic DVT, confirmed PE or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">†</a></dt>
<dd>p-value = 0.0015</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">All Treated Medical Patients During Acute Illness</td>
<td class="Rrule" align="center">1,848</td>
<td class="Rrule" align="center">1,833</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Treatment failure in evaluable patients (Day 21)<a name="footnote-reference-26" href="#footnote-26" class="Sup">*</a><br>DVT, PE, or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span></td>
<td class="Rrule" align="center">42/1,518 (2.8)<a name="footnote-reference-27" href="#footnote-27" class="Sup">†</a>
</td>
<td class="Rrule" align="center">73/1,473 (5.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total Thromboembolic Reactions (Day 21)</td>
<td class="Rrule" align="center">37/1,513 (2.5)</td>
<td class="Rrule" align="center">70/1,470 (4.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total DVT</td>
<td class="Rrule" align="center">32/1,508 (2.1)</td>
<td class="Rrule" align="center">64/1,464 (4.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Proximal DVT</td>
<td class="Rrule" align="center">29/1,518 (1.9)</td>
<td class="Rrule" align="center">60/1,474 (4.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Symptomatic VTE</td>
<td class="Rrule" align="center">10/1,759 (0.6)</td>
<td class="Rrule" align="center">17/1,740 (1.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PE</td>
<td class="Rrule" align="center">5/1,759 (0.3)</td>
<td class="Rrule" align="center">6/1,740 (0.3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden Death</span></td>
<td class="Rrule" align="center">5/1,829 (0.3)</td>
<td class="Rrule" align="center">3/1,807 (0.2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5	Patients with Cancer and Acute Symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span></h2>
<p class="First">In a prospective, multi-center, open-label, clinical trial, 676 patients with cancer and newly diagnosed, objectively confirmed acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and/or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE) were studied. Patients were randomized to either FRAGMIN 200 IU/kg subcutaneous (max 18,000 IU subcutaneous daily for one month) then 150 IU/kg subcutaneous (max 18,000 IU subcutaneous daily for five months (FRAGMIN arm) or FRAGMIN 200 IU/kg subcutaneous (max 18,000 IU subcutaneous daily for five to seven days and oral anticoagulant for six months (OAC arm). In the OAC arm, oral anticoagulation was adjusted to maintain an INR of 2 to 3. Patients were evaluated for recurrence of symptomatic <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) every two weeks for six months.</p>
<p>The median age of patients was 64 years (range: 22 to 89 years); 51.5% of patients were females; 95.3% of patients were Caucasians. Types of tumors were: gastrointestinal tract (23.7%), genito-urinary (21.5%), breast (16%), lung (13.3%), hematological tumors (10.4%) and other tumors (15.1%).</p>
<p>A total of 27 (8.0%) and 53 (15.7%) patients in the FRAGMIN and OAC arms, respectively, experienced at least one episode of an objectively confirmed, symptomatic DVT and/or PE during the 6-month study period. Most of the difference occurred during the first month of treatment (see <a href="#table16">Table 16</a>). The benefit was maintained over the 6-month study period.</p>
<a name="table16"></a><table width="100%">
<caption><span>Table 16 Recurrent VTE in Patients with Cancer (Intention to treat population)<a name="footnote-reference-28" href="#footnote-28" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="12%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Study Period</th>
<th class="Rrule" align="center" colspan="3">FRAGMIN arm</th>
<th class="Rrule" align="center" colspan="3">OAC arm</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">FRAGMIN 200 IU/kg (max. 18,000 IU) subcutaneous once daily × 1 month, then 150 IU/kg (max. 18,000 IU) subcutaneous once daily × 5 months</th>
<th class="Rrule" align="center" colspan="3">FRAGMIN 200 IU/kg (max 18,000 IU) subcutaneous once daily × 5–7 days and OAC for 6 months (target INR 2–3)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Number at Risk</th>
<th class="Rrule" align="center">Patients with VTE</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">Number at Risk</th>
<th class="Rrule" align="center">Patients with VTE</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-28" href="#footnote-reference-28">*</a></dt>
<dd>Three patients in the FRAGMIN arm and 5 patients in the OAC arm experienced more than 1 VTE over the 6-month study period.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Italics">Total</span></td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">8.0</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">15.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Week 1</span></td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">338</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Weeks 2–4</span></td>
<td class="Rrule" align="center">331</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">327</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">7.6</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Weeks 5–28</td>
<td class="Rrule" align="center">307</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">5.2</td>
<td class="Rrule" align="center">284</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">7.0</td>
</tr>
</tbody>
</table>
<p>In the intent-to-treat population that included all randomized patients, the primary comparison of the cumulative probability of the first VTE recurrence over the 6-month study period was statistically significant (p &lt; 0.01) in favor of the FRAGMIN arm, with most of the treatment difference evident in the first month.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">After first penetration of the rubber stopper, store the multiple-dose vials at room temperature for up to 2 weeks.</p>
<table width="100%">
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Dosage Form</th>
<th class="Rrule" align="center">Strength</th>
<th class="Rrule" align="center">Package Size</th>
<th class="Rrule" align="center">NDC Number</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-29" href="#footnote-reference-29">*</a></dt>
<dd>Single-dose prefilled syringe, affixed with a 27-gauge × 1/2 inch needle and preassembled with UltraSafe Passive™ Needle Guard devices.</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">†</a></dt>
<dd>Single-dose graduated syringe, affixed with a 27-gauge × 1/2 inch needle and preassembled with UltraSafe Passive™ Needle Guard devices. UltraSafe Passive™ Needle Guard is a trademark of Safety Syringes, Inc.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="3">Single-dose prefilled syringe<a name="footnote-reference-29" href="#footnote-29" class="Sup">*</a>
</td>
<td class="Rrule" align="center">2,500 IU / 0.2 mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0195-02</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">5,000 IU / 0.2 mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0196-02</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center" valign="top">7,500 IU / 0.3 mL</td>
<td class="Rrule" align="center" valign="top">10 Syringes</td>
<td class="Rrule" align="center" valign="top">0069-0206-02</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Single-dose graduated syringe<a name="footnote-reference-30" href="#footnote-30" class="Sup">†</a>
</td>
<td class="Rrule" align="center">10,000 IU / mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0217-02</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Single-dose prefilled syringe<a href="#footnote-29" class="Sup">*</a>
</td>
<td class="Rrule" align="center">12,500 IU / 0.5 mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0220-02</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">15,000 IU / 0.6 mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0223-02</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">18,000 IU / 0.72 mL</td>
<td class="Rrule" align="center">10 Syringes</td>
<td class="Rrule" align="center">0069-0228-02</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Multiple dose vial</td>
<td class="Rrule" align="center">95,000 IU / 3.8 mL (25,000 IU / mL)</td>
<td class="Rrule" align="center">3.8 mL vial</td>
<td class="Rrule" align="center">0069-0232-01</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, inform the patients to watch for signs and symptoms of spinal or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span>, such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> (especially in the lower limbs) and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>. If any of these symptoms occur the patient should contact his or her physician immediately.</p>
<p>Additionally, the use of aspirin and other NSAIDs may enhance the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Discontinue their use prior to dalteparin therapy whenever possible; if co-administration is essential, the patient's clinical and laboratory status should be closely monitored [<span class="Italics">see <a href="#S7">Drug Interactions (7)</a></span>].</p>
<p>Inform patients:</p>
<ul class="Disc">
<li>of the instructions for injecting FRAGMIN if their therapy is to continue after discharge from the hospitals.</li>
<li>it may take them longer than usual to stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>they may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and/or bleed more easily when they are treated with FRAGMIN.</li>
<li>they should report any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, or signs of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of dark red spots under the skin) to their physician [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2)</a></span>].</li>
<li>to tell their physicians and dentists they are taking FRAGMIN and/or any other product known to affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> before any surgery is scheduled and before any new drug is taken [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</li>
<li>to tell their physicians and dentists of all medications they are taking, including those obtained without a prescription, such as aspirin or other NSAIDs [<span class="Italics">see <a href="#S7">Drug Interactions (7)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">FRAGMIN is a registered trademark of Pfizer Health AB.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-03.jpg"></p>
<p>LAB-0058-12.0</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2500 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.2 mL</span><br>NDC 0069-0195-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">2500 IU per 0.2 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017<br><span class="Bold">Rx only</span></p>
<p>10005266-01<br>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2500 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.2 mL Single-dose prefilled syringe</span><br>NDC 0069-0195-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">2500 IU per 0.2 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005281-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2500 IU Syringe Carton</h1>
<p class="First">NDC 0069-0195-02<br>Contains 10 of NDC 0069-0195-01</p>
<p><span class="Bold">10 x 0.2 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">2500 IU per 0.2 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2500 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5000 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.2 mL</span><br>NDC 0069-0196-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">5000 IU per 0.2 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017<br><span class="Bold">Rx only</span></p>
<p>10005265-01<br>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5000 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.2 mL Single-dose prefilled syringe</span><br>NDC 0069-0196-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">5000 IU per 0.2 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005280-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5000 IU Syringe Carton</h1>
<p class="First">NDC 0069-0196-02<br>Contains 10 of NDC 0069-0196-01</p>
<p><span class="Bold">10 x 0.2 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">5000 IU per 0.2 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5000 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7500 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.3 mL</span><br>NDC 0069-0206-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">7500 IU per 0.3 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017<br><span class="Bold">Rx only</span></p>
<p>10005264-01<br>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 7500 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.3 mL Single-dose prefilled syringe</span><br>NDC 0069-0206-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">7500 IU per 0.3 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005279-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 7500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7500 IU Syringe Carton</h1>
<p class="First">NDC 0069-0206-02<br>Contains 10 of NDC 0069-0206-01</p>
<p><span class="Bold">10 x 0.3 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">7500 IU per 0.3 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 7500 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-12.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-26"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe Label</h1>
<p class="First"><span class="Bold">1 mL</span></p>
<p>NDC 0069-0217-01</p>
<p><span class="Bold">Fragmin<span class="Sup">®</span></span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">10,000 IU per 1 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017</p>
<p><span class="Bold">Rx only</span><br>10005263-01<br>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-13.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-27"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">1 mL Single-dose graduated syringe</span><br>NDC 0069-0217-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">10,000 IU per 1 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005278-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-14.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-28"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe Carton</h1>
<p class="First">NDC 0069-0217-02<br>Contains 10 of NDC 0069-0217-01</p>
<p><span class="Bold">10 x 1 mL Single-dose graduated syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">10,000 IU per 1 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10,000 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-15.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-29"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.5 mL</span><br>NDC 0069-0220-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">12,500 IU per 0.5 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017</p>
<p>10005222-01<br><span class="Bold">Rx only</span></p>
<p>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-16.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-30"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.5 mL Single-dose prefilled syringe</span><br>NDC 0069-0220-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">12,500 IU per 0.5 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005277-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-17.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-31"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe Carton</h1>
<p class="First">NDC 0069-0220-02<br>Contains 10 of NDC 0069-0220-01</p>
<p><span class="Bold">10 x 0.5 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">12,500 IU per 0.5 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 12,500 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-18.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-32"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.6 mL</span><br>NDC 0069-0223-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">15,000 IU per 0.6 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017</p>
<p>10005221-01<br><span class="Bold">Rx only</span></p>
<p>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-19.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-33"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.6 mL Single-dose prefilled syringe</span><br>NDC 0069-0223-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">15,000 IU per 0.6 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005276-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-20.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-34"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe Carton</h1>
<p class="First">NDC 0069-0223-02<br>Contains 10 of NDC 0069-0223-01</p>
<p><span class="Bold">10 x 0.6 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">15,000 IU per 0.6 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15,000 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-21.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-35"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe Label</h1>
<p class="First"><span class="Bold">0.72 mL</span><br>NDC 0069-0228-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">18,000 IU per 0.72 mL</span></p>
<p>Pfizer Labs<br>Division of Pfizer Inc<br>NY, NY 10017</p>
<p>10005220-01<br><span class="Bold">Rx only</span></p>
<p>LOT<br>EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-22.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-36"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Store at controlled room temperature<br>20° to 25°C (68° to 77°F) [see USP].</span></p>
<p><span class="Bold">DOSAGE AND USE</span>: See accompanying<br>prescribing information.</p>
<p>Distributed by<br>Pfizer Labs<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><span class="Bold">0.72 mL Single-dose prefilled syringe</span><br>NDC 0069-0228-01</p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">18,000 IU per 0.72 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>10005275-01</p>
<p><span class="Bold">To Open Pull Tab</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-23.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-37"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe Carton</h1>
<p class="First">NDC 0069-0228-02<br>Contains 10 of NDC 0069-0228-01</p>
<p><span class="Bold">10 x 0.72 mL Single-dose prefilled syringes,<br>preassembled with needle guards</span></p>
<p><span class="Bold">Fragmin</span><span class="Sup">®</span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">18,000 IU per 0.72 mL*</span></p>
<p>For subcutaneous injection</p>
<p><span class="Bold Italics">Pfizer Injectables</span><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 18,000 IU Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-24.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-38"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 95,000 IU Multi-Dose Vial Label</h1>
<p class="First">NDC 0069-0232-01</p>
<p><span class="Bold">3.8 mL multiple-dose vial</span></p>
<p><span class="Bold">Fragmin<span class="Sup">®</span></span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">95,000 IU/3.8 mL</span><br>(25,000 IU/mL)</p>
<p>For subcutaneous injection<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 95,000 IU Multi-Dose Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-25.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-39"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 95,000 IU Multi-Dose Vial Carton</h1>
<p class="First">NDC 0069-0232-01</p>
<p><span class="Bold">3.8 mL multiple-dose vial</span></p>
<p><span class="Bold">Fragmin<span class="Sup">®</span></span><br>(dalteparin sodium injection)</p>
<p><span class="Bold">95,000 IU/3.8 mL</span><br>(25,000 IU/mL)</p>
<p>For subcutaneous injection</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 95,000 IU Multi-Dose Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;name=fragmin-26.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0195</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">2500 [iU]  in 0.2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0195-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0195-01</td>
<td class="formItem">0.2 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0196</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">5000 [iU]  in 0.2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0196-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0196-01</td>
<td class="formItem">0.2 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0206</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">7500 [iU]  in 0.3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0206-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0206-01</td>
<td class="formItem">0.3 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0217</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">10000 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0217-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0217-01</td>
<td class="formItem">1 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0220</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">12500 [iU]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0220-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0220-01</td>
<td class="formItem">0.5 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0223</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">15000 [iU]  in 0.6 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0223-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0223-01</td>
<td class="formItem">0.6 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0228</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">18000 [iU]  in 0.72 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0228-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0228-01</td>
<td class="formItem">0.72 mL in 1 SYRINGE; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FRAGMIN 		
					</strong><br><span class="contentTableReg">dalteparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0232</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DALTEPARIN SODIUM</strong> (DALTEPARIN) </td>
<td class="formItem">DALTEPARIN SODIUM</td>
<td class="formItem">25000 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">14 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0232-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.8 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020287</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b4fcf18a-0fb6-4c87-969c-4f228969d135</div>
<div>Set id: 23527b8b-9b28-4e6d-9751-33b143975ac7</div>
<div>Version: 4</div>
<div>Effective Time: 20150702</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
